REG - Indivior PLC - Indivior Provides Historical Financials in US GAAP

IndiviorAnnouncement

09/01/2025 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250109:nRSI6619Sa&default-theme=true

RNS Number : 6619S  Indivior PLC  09 January 2025

 

 

Indivior Provides Historical Financials in US GAAP

Slough, UK, and Richmond, VA, January 9, 2025 - Indivior PLC (NASDAQ/LSE:
INDV) today has provided historical financial information in US GAAP and
certain reconciliations to IFRS as part of its transition to a US primary
listing.

On May 23, 2024, shareholders overwhelmingly approved moving Indivior's
primary listing to the US. Transitioning to US GAAP reporting in FY 2025 is
the next logical next step in the Group's transition to the US. US GAAP
financial statements are expected to help facilitate greater US analyst and
investor interest and are required for inclusion in major US equity indices
the Group is targeting.

The historical US GAAP financial information along with reconciliations to
IFRS financials for certain periods can be found on the Group's website at
https://www.indivior.com/en/investors/ifrs-to-us-gaap-conversion
(https://www.indivior.com/en/investors/ifrs-to-us-gaap-conversion) .

The Group's most recently published guidance provided to the market on October
24, 2024, in respect of the year ended December 31, 2024, was issued on an
IFRS basis.

With its FY 2024 IFRS results release in February 2025, the Group will provide
FY 2025 guidance items on a U.S. GAAP basis as well as FY 2024 comparatives on
a U.S. GAAP basis. Group results thereafter will be reported on a U.S. GAAP
basis and the Group will provide its results on SEC Form 10-K and SEC Form
10-Q.

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat substance use disorders (SUD). Our
vision is that all patients around the world will have access to
evidence-based treatment for the chronic conditions and co-occurring disorders
of SUD. Indivior is dedicated to transforming SUD from a global human crisis
to a recognized and treated chronic disease. Building on its global portfolio
of OUD treatments, Indivior has a pipeline of product candidates designed to
expand on its heritage in this category. Headquartered in the United
States in Richmond, VA, Indivior employs over 1,000 individuals globally and
its portfolio of products is available in over 30 countries worldwide.
Visit www.indivior.com
(https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4271839-1%26h%3D3117038971%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4245151-1%2526h%253D1246464342%2526u%253Dhttps%25253A%25252F%25252Fwww.indivior.com%25252Fen%2526a%253Dwww.indivior.com%26a%3Dwww.indivior.com&data=05%7C02%7Ctimothy.owens%40Indivior.com%7C1c0870687cb54346b25d08dd1eda91aa%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C638700646286751522%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=kUTf6Q0dQRiy7lv5uIiD%2FsokBwKjYPtyVN%2BBjF1Vlt8%3D&reserved=0)
 to learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior
(https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4271839-1%26h%3D2950697406%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4245151-1%2526h%253D27799095%2526u%253Dhttp%25253A%25252F%25252Fwww.linkedin.com%25252Fcompany%25252Findivior%2526a%253Dwww.linkedin.com%25252Fcompany%25252Findivior.%26a%3Dwww.linkedin.com%252Fcompany%252Findivior&data=05%7C02%7Ctimothy.owens%40Indivior.com%7C1c0870687cb54346b25d08dd1eda91aa%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C638700646286775409%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=Qa1ogrVVoioUOO329W9FfIIAUpJFy0pJRBYqcn27khY%3D&reserved=0)
.

 

 

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-402-7123 or jason.thompson@indivior.com
(mailto:jason.thompson@indivior.com)

 

Tim Owens

Director, Investor Relations

Tel: 804-263-3978 or timothy.owens@indivior.com
(mailto:timothy.owens@indivior.com)

 

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPKFBKBBKBPDK